GPD1L Human
Glycerol-3-Phosphate Dehydrogenase 1 Like Human Recombinant
Cat. No.
BT9330
Source
Escherichia Coli.
Synonyms
Glycerol-3-phosphate dehydrogenase 1-like protein, GPD1-L, GPD1L, KIAA0089.
Appearance
Sterile Filtered colorless solution.
Purity
Greater than 95.0% as determined by SDS-PAGE.
Usage
THE BioTek's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
Shipped with Ice Packs 
In Stock 
Description
GPD1L Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 371 amino acids (1-351 a.a.) and having a molecular mass of 40.6kDa.
GPD1L is fused to a 20 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.
GPD1L is fused to a 20 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.
Product Specs
Introduction
GPD1L, or Glycerol-3-phosphate dehydrogenase 1-like protein, plays a crucial role in converting sn-glycerol 3-phosphate to glycerone phosphate. This protein is primarily located in the cytoplasm and is associated with the plasma membrane. At the plasma membrane, GPD1L binds to SCN5A, the alpha subunit of the voltage-gated sodium channel, type V. Genetic mutations affecting the GPD1L gene have been linked to serious medical conditions like SIDS (sudden infant death syndrome) and Brugada syndrome type 2, a type of inherited cardiac arrhythmia.
Description
Recombinant GPD1L Human, produced in E. coli, is a single, non-glycosylated polypeptide chain consisting of 371 amino acids (specifically, amino acids 1 through 351). With a molecular weight of 40.6 kDa, this protein is fused to a 20 amino acid His-tag at its N-terminus. Purification is achieved using proprietary chromatographic techniques.
Physical Appearance
Clear, colorless solution that has been sterilized through filtration.
Formulation
The GPD1L protein solution is provided at a concentration of 1 mg/ml. It is formulated in a buffer containing 20mM Tris-HCl (pH 8.0), 20% glycerol, and 1mM DTT.
Stability
For short-term storage (up to 2-4 weeks), the product can be kept at 4°C. For extended storage, it is recommended to freeze the product at -20°C. Adding a carrier protein like HSA or BSA (0.1%) is advisable for long-term storage. Repeated freezing and thawing should be avoided.
Purity
Purity of the GPD1L protein is greater than 95%, as determined by SDS-PAGE analysis.
Synonyms
Glycerol-3-phosphate dehydrogenase 1-like protein, GPD1-L, GPD1L, KIAA0089.
Source
Escherichia Coli.
Amino Acid Sequence
MGSSHHHHHH SSGLVPRGSH MAAAPLKVCI VGSGNWGSAV AKIIGNNVKK LQKFASTVKM WVFEETVNGR KLTDIINNDH ENVKYLPGHK LPENVVAMSN LSEAVQDADL LVFVIPHQFI HRICDEITGR VPKKALGITL IKGIDEGPEG LKLISDIIRE KMGIDISVLM GANIANEVAA EKFCETTIGS KVMENGLLFK ELLQTPNFRI TVVDDADTVE LCGALKNIVA VGAGFCDGLR CGDNTKAAVI RLGLMEMIAF ARIFCKGQVS TATFLESCGV ADLITTCYGG RNRRVAEAFA RTGKTIEELE KEMLNGQKLQ GPQTSAEVYR ILKQKGLLDK FPLFTAVYQI CYESRPVQEM LSCLQSHPEH T.
Product Science Overview
Structure and Expression
Function
GPD1L plays a significant role in regulating cardiac sodium current. It binds to the sodium channel, voltage-gated, type V, alpha subunit (SCN5A). Decreased enzymatic activity of GPD1L leads to increased levels of glycerol-3-phosphate, which activates the DPD1L-dependent SCN5A phosphorylation pathway. This may ultimately result in decreased sodium current. Additionally, alterations in the NAD(H) balance induced by GPD1L can also reduce cardiac sodium current .
Clinical Significance
Mutations or defects in the GPD1L gene are associated with several medical conditions:
- Brugada Syndrome Type 2 (BRS2): This is an autosomal dominant tachyarrhythmia characterized by right bundle branch block and ST segment elevation on an electrocardiogram (ECG). It can cause the ventricles to beat so fast that the blood is prevented from circulating efficiently in the body, leading to fainting or sudden death if the heart is not reset .
- Sudden Infant Death Syndrome (SIDS): GPD1L defects are also linked to SIDS, which is the sudden death of an infant younger than one year that remains unexplained after a thorough case investigation, including a complete autopsy, examination of the death scene, and review of clinical history .
Quick Inquiry
Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
